T1	Participants 601 631;632 657	atients with first-line NSCLC. METHODS From 2006 to 2009
T2	Participants 674 814	patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology.
